AstraZeneca is investing $300 million in a state-of-the-art facility in Rockville, the company announced Tuesday. The facility is part of the launch of its life-saving cell therapy platforms in the United States for critical cancer trials and future commercial supply.
It is expected to create more than 150 new highly-skilled jobs to initially focus on manufacturing T-cell therapies to enable clinical trials to be conducted around the world. Over time, the site may expand its focus to support other disease areas. The site represents the latest investment in cell therapy for AstraZeneca following collaborations with Quell therapeutics, AbelZeta, Cellectis, and the acquisition of Neogene Therapeutics.
“We are incredibly excited that more than 150 new highly skilled jobs are being created to bring our scientific work and therapies to clinical trials which could transform the lives of patients around the world,” Pam Cheng, Executive Vice President of Global Operations & IT and Chief Sustainability Officer, AstraZeneca, said. “This new $300 million investment will accelerate our ambition to make next-generation cell therapy a reality, ensuring that we are ready to scale and meet the demands of patients.”
The facility in Rockville is located less than 5 miles away from one of the company’s five global research and development centers and sits within the booming life sciences corridor in Maryland. Close to several universities, the life sciences ecosystem provides an attractive environment for recruiting new and experienced talent.